MD1374F2 - Anticorpi monoclonali imunostimulatori, procedeu de obtinere a acestora, linii celulare, metoda de tratare a maladiilor si compozitie farmaceutica - Google Patents

Anticorpi monoclonali imunostimulatori, procedeu de obtinere a acestora, linii celulare, metoda de tratare a maladiilor si compozitie farmaceutica

Info

Publication number
MD1374F2
MD1374F2 MD96-0296A MD960296A MD1374F2 MD 1374 F2 MD1374 F2 MD 1374F2 MD 960296 A MD960296 A MD 960296A MD 1374 F2 MD1374 F2 MD 1374F2
Authority
MD
Moldova
Prior art keywords
proposed
antibody
monoclonal
pharmaceutical composition
lymphocytes
Prior art date
Application number
MD96-0296A
Other languages
English (en)
Other versions
MD1374G2 (ro
Inventor
Britta Hardy
Avraham Novogrodsky
Original Assignee
Mor Research Applic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applic Ltd filed Critical Mor Research Applic Ltd
Publication of MD1374F2 publication Critical patent/MD1374F2/ro
Publication of MD1374G2 publication Critical patent/MD1374G2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)
MD96-0296A 1994-01-31 1995-01-30 Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică MD1374G2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them
PCT/US1995/001137 WO1995020605A1 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies

Publications (2)

Publication Number Publication Date
MD1374F2 true MD1374F2 (ro) 1999-12-31
MD1374G2 MD1374G2 (ro) 2000-09-30

Family

ID=11065761

Family Applications (1)

Application Number Title Priority Date Filing Date
MD96-0296A MD1374G2 (ro) 1994-01-31 1995-01-30 Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică

Country Status (20)

Country Link
US (1) US5897862A (ro)
EP (1) EP0742795B1 (ro)
JP (1) JP3478398B2 (ro)
CN (1) CN1052733C (ro)
AT (1) ATE171461T1 (ro)
AU (1) AU693526B2 (ro)
CA (1) CA2182289C (ro)
DE (1) DE69504955T2 (ro)
DK (1) DK0742795T3 (ro)
EE (1) EE03285B1 (ro)
ES (1) ES2124533T3 (ro)
FI (1) FI963004L (ro)
IL (1) IL108501A (ro)
LT (1) LT4225B (ro)
LV (1) LV11624B (ro)
MD (1) MD1374G2 (ro)
MX (1) MX9603080A (ro)
NO (1) NO317020B1 (ro)
RU (1) RU2155190C2 (ro)
WO (1) WO1995020605A1 (ro)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2145634C1 (ru) * 1998-03-12 2000-02-20 Булычева Татьяна Ивановна Штамм культивируемых клеток мышиной гибридомы, используемый для получения моноклональных антител к ядрышковому антигену, ассоциированному с клеточной пролиферацией
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
RU2192888C1 (ru) * 2001-02-15 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома
CN1294148C (zh) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
HRP20120845T1 (hr) * 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
US20090123413A1 (en) * 2004-08-23 2009-05-14 Britta Hardy Use of bat monoclonal antibody for immunotherapy
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
BR122017025062B8 (pt) * 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
MD3972C2 (ro) * 2009-03-11 2010-07-31 Ион МЕРЕУЦЭ Remediu şi metodă de tratament al stărilor precanceroase
CA2840018C (en) 2011-07-24 2019-07-16 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
HUE068868T2 (hu) 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
IL260021B (en) 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
MX2019002867A (es) 2016-09-19 2019-11-12 Celgene Corp Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation

Also Published As

Publication number Publication date
NO963168L (no) 1996-09-27
FI963004A7 (fi) 1996-09-27
DE69504955D1 (de) 1998-10-29
NO963168D0 (no) 1996-07-29
LT96115A (en) 1997-05-26
RU2155190C2 (ru) 2000-08-27
EP0742795A1 (en) 1996-11-20
IL108501A (en) 1998-10-30
CN1052733C (zh) 2000-05-24
DE69504955T2 (de) 1999-05-27
IL108501A0 (en) 1994-05-30
EP0742795B1 (en) 1998-09-23
LV11624B (en) 1997-06-20
US5897862A (en) 1999-04-27
WO1995020605A1 (en) 1995-08-03
AU693526B2 (en) 1998-07-02
FI963004L (fi) 1996-09-27
ES2124533T3 (es) 1999-02-01
JPH09508390A (ja) 1997-08-26
CN1145077A (zh) 1997-03-12
FI963004A0 (fi) 1996-07-29
EE03285B1 (et) 2000-08-15
CA2182289C (en) 2003-10-21
JP3478398B2 (ja) 2003-12-15
AU1868695A (en) 1995-08-15
MX9603080A (es) 1998-01-31
DK0742795T3 (da) 1999-06-14
CA2182289A1 (en) 1995-08-03
LV11624A (en) 1996-12-20
LT4225B (en) 1997-10-27
NO317020B1 (no) 2004-07-26
MD1374G2 (ro) 2000-09-30
ATE171461T1 (de) 1998-10-15

Similar Documents

Publication Publication Date Title
MD1374F2 (ro) Anticorpi monoclonali imunostimulatori, procedeu de obtinere a acestora, linii celulare, metoda de tratare a maladiilor si compozitie farmaceutica
Wendling et al. Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis
Hodgkin et al. Separation of events mediating B cell proliferation and Ig production by using T cell membranes and lymphokines.
JP3769014B2 (ja) 多段カスケード型追加免疫ワクチン
Handman et al. Stage-specific, strain-specific, and cross-reactive antigens of Leishmania species identified by monoclonal antibodies
RU96116984A (ru) Иммуностимуляторные моноклональные антитела
KR920703036A (ko) 자가면역 및 악성 질환 치료제로서의 t 세포 수용체 펩타이드
Moroz et al. Cell-surface immunoglobulin of human thymus cells and its biosynthesis in vitro
ATE212038T1 (de) Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung
JP2002531123A5 (ro)
WO1995020605A9 (en) Immuno-stimulatory monoclonal antibodies
PT1331944E (pt) Utilização de anticorpos monoclonais específicos para cd28 para a estimulação de células sanguíneas que não comportam qualquer cd28
ZA891861B (en) Monoclonal antibodies
CA2284079A1 (en) Immunotoxins and methods of inducing immune tolerance
Van Laar et al. Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis
Segal et al. Specific blocking in vitro of antibody synthesis by affinity labelling reagents
JPH10505325A (ja) 治療剤としてのｔ細胞に対する抗体
US7118924B2 (en) Method for producing human antibodies in SCID mice which uses dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents
CA2134083C (en) Prophylactic and therapeutic agents for autoimmune diseases
EP0525570A2 (en) Anti-idiotypic antibodies that mimic TNF
JPH01501793A (ja) 透明帯に対する免疫化による避妊のための方法
EP0282343A2 (en) Method to stimulate the immune response to specific antigens
Eig et al. Complete inhibition of the expression of an idiotype by a mechanism of B-cell dominance.
Gorczynski et al. Altered tumor growth in vivo after immunization of mice with antitumor antibodies
Cobbold et al. Immunosuppression with monoclonal antibodies—rules for effective serotherapy

Legal Events

Date Code Title Description
PD99 Pending application